Značajni radovi o renalnoj anemiji
2007 Feb
Bunn HF.
New agents that stimulate erythropoiesis.
Nephrol Dial Transplant 2006 Jul; 21 (Suppl 4): iv169
2006 Dec
de Francisco AL, Sulowicz W, Klinger M, Niemczyk S, Vargemezis V, Metivier F, Dougherty FC, Oguey D; BA16260 Study Invesigators.
Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study International
Journal of Clinical Practice 2006 Dec;60(12):1687-96
2006 Dec
Kerr PG.
Renal anaemia: Recent developments, innovative approaches and future directions for improved management (Review Article).
Nephrology (Carlton). 2006 Dec;11(6):542-8.
2006 Dec
Rastogi A, Nissenson AR.
New approaches to the management of anemia of chronic kidney disease: Beyond Epogen and Infed.
Kidney Int Suppl. 2006 Dec;(104):S14-6.
2006 Nov
Macdougall I, et al.
Pharmacokinetics and Pharmacodynamics of Intravenous and Subcutaneous Continuous Erythropoietin Receptor Activator (C.E.R.A.) in Patients with Chronic Kidney Disease.
Clin J Am Soc Nephrol. 2006 Nov;1:1211-1215.
2006 Oct
Fan Q, Leuther KK, Holmes CP, Fong KL, Zhang J, Velkovska S, Chen MJ, Mortensen RB, Leu K, Green JM, Schatz PJ, Woodburn KW.
Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia.
Exp Hematol. 2006 Oct;34(10):1303-11
2006 Oct
Sharma B, Ryan MH, Boven K.
Reactions to Eprex's adverse reactions.
Nat Biotechnol. 2006 Oct;24(10):1199-200; author reply 1200.
2006 Sep
Macdougall IC, Eckardt KU.
Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia.
Lancet. 2006 Sep 9;368(9539):947-53.
2006 Sep
Stead RB, Lambert J, Wessels D, Iwashita JS, Leuther KK, Woodburn KW, Schatz PJ, Okamoto DM, Naso R, Duliege AM.
Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers.
2006 Sep 15;108(6):1830-4.
2006
Sulowicz W.
C.E.R.A. (Continuous Erythropoietin Receptor Activator): A new perspective in anaemia management.
BANTAO Journal 2006:4:77-80.
2006 Jul
Macdougall IC.
Recent advances in erythropoietic agents in renal anemia.
Semin Nephrol. 2006 Jul;26(4):313-8.
2006 Jun
Schellekens H, Jiskoot W.
Eprex-associated pure red cell aplasia and leachates.
Nat Biotechnol. 2006 Jun;24(6):613-4.
2006 Jun
Bernhardt WM, Campean V, Kany S, Jurgensen JS, Weidemann A, Warnecke C, Arend M, Klaus S, Gunzler V, Amann K, Willam C, Wiesener MS, Eckardt KU.
Preconditional activation of hypoxia-inducible factors ameliorates ischemic acute renal failure.
J Am Soc Nephrol. 2006 Jul;17(7):1970-8. Epub 2006 Jun 8.
2005 Nov
Macdougall IC.
CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia.
Curr Hematol Rep. 2005 Nov;4(6):436-40.
2005
Crommelin D, Bermejo T, Bissig M, Damiaans J, Kramer I, Rambourg P, Scroccaro G, Strukelj B, Tredree R, Ronco C.
Biosimilars, generic versions of the first generation of therapeutic proteins: do they exist?
Contrib Nephrol. 2005;149:287-94.
2005 May
Schellekens H.
Follow-on biologics: challenges of the "next generation".
Nephrol Dial Transplant. 2005 May;20 Suppl 4:iv31-36.
